Extracorporeal support can significantly increase number of organs available for transplant
Using heart-lung support technology, the University of Michigan
Using heart-lung support technology, the University of Michigan
Princeton University researchers have developed a way to use a laser to measure people’s blood sugar, and, with more work to shrink the laser system to a portable size, the technique could allow diabetics to check their condition without pricking themselves to draw blood.
‘We are working hard to turn engineering solutions into useful tools for people to use in their daily lives,’ said Claire Gmachl, the Eugene Higgins Professor of Electrical Engineering and the project’s senior researcher. ‘With this work we hope to improve the lives of many diabetes sufferers who depend on frequent blood glucose monitoring.’
In an article, the researchers describe how they measured blood sugar by directing their specialized laser at a person’s palm. The laser passes through the skin cells, without causing damage, and is partially absorbed by the sugar molecules in the patient’s body. The researchers use the amount of absorption to measure the level of blood sugar.
Sabbir Liakat, the paper’s lead author, said the team was pleasantly surprised at the accuracy of the method. Glucose monitors are required to produce a blood-sugar reading within 20 percent of the patient’s actual level; even an early version of the system met that standard. The current version is 84 percent accurate, Liakat said.
‘It works now but we are still trying to improve it,’ said Liakat, a graduate student in electrical engineering.
When the team first started, the laser was an experimental setup that filled up a moderate-sized workbench. It also needed an elaborate cooling system to work. Gmachl said the researchers have solved the cooling problem, so the laser works at room temperature. The next step is to shrink it.
‘This summer, we are working to get the system on a mobile platform to take it places such as clinics to get more measurements,’ Liakat said. ‘We are looking for a larger dataset of measurements to work with.’
The key to the system is the infrared laser’s frequency. What our eyes perceive as colour is created by light’s frequency (the number of light waves that pass a point in a certain time). Red is the lowest frequency of light that humans normally can see, and infrared’s frequency is below that level. Current medical devices often use the ‘near-infrared,’ which is just beyond what the eye can see. This frequency is not blocked by water, so it can be used in the body, which is largely made up of water. But it does interact with many acids and chemicals in the skin, so it makes it impractical to use for detecting blood sugar.
Mid-infrared light, however, is not as much affected by these other chemicals, so it works well for blood sugar. But mid-infrared light is difficult to harness with standard lasers. It also requires relatively high power and stability to penetrate the skin and scatter off bodily fluid. (The target is not the blood but fluid called dermal interstitial fluid, which has a strong correlation with blood sugar.)
The breakthrough came from the use of a new type of device that is particularly adept at producing mid-infrared frequencies
The American College of Chest Physicians (CHEST) announces the immediate releasePDF of Care of the Critically Ill and Injured During Pandemics and Disasters: CHEST Consensus Statement today in the Online First section of the journal CHEST while the global health-care community cares for patients with the Ebola virus. The consensus statement aims to guide ethical decision-making, coordination of care, resource conservation, and research in crises. The statement was developed by over 100 clinicians and experts representing a broad variety and scope of clinical fields from more than nine countries. It offers the latest evidence-informed suggestions on how to best prepare and manage the critically ill and injured during large-scale disasters and pandemics.
Ethical approval has been given for a study where some cardiac arrest patients will be given a dummy pill, rather than adrenaline to kick-start their heart. There are concerns the resuscitation drug, used for more than 50 years, can do more harm than good. But the study will mean some patients across England and Wales being given a placebo without their consent.Experts say the research throws up a number of ethical challenges. More than 50,000 people suffer cardiac arrests outside of hospitals each year in the UK. During arrests their hearts stop beating completely and most people do not survive. Currently only 8% leave hospital alive. Paramedics follow a protocol for anyone found without a heartbeat – this involves chest compressions, shocking the heart with a defibrillator and giving a shot of adrenaline if shocks don
Results from a new meta-analysis have found that an anticoagulation regimen of bivalirudin vs. heparin increases the rate of MI and stent thrombosis while decreasing the risk for major bleeding in patients undergoing percutaneous coronary intervention (PCI). The extent of bleeding reduction with bivalirudin was dependent on concomitant glycoprotein IIb/IIIa inhibitor use, according to the researchers.
Indiana University researchers have detected new early-warning signs of the potential loss of sight associated with diabetes. This discovery could have far-reaching implications for the diagnosis and treatment of diabetic retinopathy.
A significant breakthrough could revolutionise surgical practice and regenerative medicine. A team led by Ludwik Leibler from the Laboratoire Mati
By 2015, all baby boomers will be 50 or older. In an editorial for the Journal of Addictions Nursing, Savage writes that, unlike members of previous generations, many of these individuals have been using alcohol (and other drugs) for their entire adult lives. There are consequences.
Fecal colour and consistency are well-known markers of digestive health in both children and adults, but paying attention to a newborn
April 2024
The medical devices information portal connecting healthcare professionals to global vendors
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlyCookie settingsWe may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Privacy policy